340B Program Disruption: How Drugmaker Lawsuits Could Reshape ASC Pharmacy Revenue

While ASC leaders focus on prior authorization delays and staffing costs, a quieter battle over drug pricing definitions could wipe out pharmacy savings that many centers rely on to maintain margins.

The Hidden Revenue Risk

Most ambulatory surgery centers participating in the 340B Drug Pricing Program treat their discounted pharmaceutical purchases as a given. These savings, which can reduce drug costs by 25-50% depending on the medication, have become built into operating budgets and margin calculations. But ongoing litigation between pharmaceutical manufacturers and the Health Resources and Services Administration (HRSA) threatens to fundamentally alter which patients qualify for 340B pricing.

The financial exposure extends beyond obvious high-cost medications. ASCs performing orthopedic, ophthalmology, and pain management procedures often rely on 340B savings for routine pharmaceuticals used across multiple cases daily. When those savings disappear for a subset of patients, the impact multiplies quickly across case volumes.

What the Lawsuits Actually Challenge

The core dispute centers on patient eligibility definitions rather than the program's existence. Pharmaceutical companies argue that HRSA's interpretation of which patients qualify as "340B patients" exceeds the agency's statutory authority. The lawsuits specifically challenge whether patients can be considered eligible for 340B pricing when they receive care at off-site locations or through contracted relationships.

For ASCs, this matters because many participate in 340B through hospital affiliations or federally qualified health center partnerships. If courts narrow the patient definition, ASCs could lose 340B eligibility for patients they currently serve under these arrangements.

The timing creates additional uncertainty. While litigation proceeds, some pharmaceutical manufacturers have unilaterally restricted 340B pricing for contract pharmacy arrangements. Others continue to honor existing contracts while the legal questions resolve. This patchwork approach makes it difficult for ASC leaders to predict which medications will qualify for discounted pricing from month to month.

Immediate Financial Planning Steps

ASC CFOs should audit their current 340B savings by medication and patient volume. Most centers lack visibility into how much of their pharmaceutical budget depends on 340B pricing because the savings are built into purchase prices rather than tracked as separate line items.

Start by requesting detailed reports from your pharmaceutical suppliers showing 340B versus non-340B pricing for your top 20 medications by volume and cost. This baseline helps quantify the financial risk if patient definitions change.

Review your hospital or FQHC partnership agreements to understand how 340B eligibility determinations are made. Some contracts include specific language about patient qualification criteria, while others rely on broad interpretations that could be vulnerable to legal challenges.

Consider negotiating alternative pricing arrangements with pharmaceutical suppliers for scenarios where 340B savings become unavailable. Group purchasing organizations often have non-340B contracts that provide smaller but more predictable discounts.

Revenue Cycle Implications

Changes to 340B patient definitions could force ASCs to implement new tracking and documentation requirements. If eligibility becomes more restrictive, centers may need systems to identify qualifying patients before procedures rather than applying 340B pricing broadly.

This operational complexity has billing implications. ASCs currently using 340B savings to improve margins on cases with fixed reimbursement rates may need to adjust their pricing strategies if those savings disappear for certain patient populations.

The documentation burden could also increase. Narrower patient definitions typically require more detailed record-keeping to demonstrate eligibility, adding administrative costs that partially offset the savings.

What Leaders Should Monitor

Track which pharmaceutical manufacturers are restricting 340B pricing for your specific partnership arrangements. AbbVie's lawsuit against HRSA represents one of several ongoing legal challenges, and different manufacturers may take varying approaches while litigation proceeds.

Stay connected with your hospital or FQHC partners about their 340B compliance strategies. These organizations often have dedicated staff monitoring regulatory changes and court decisions that could affect ASC partnerships.

Review quarterly financial reports to identify trends in pharmaceutical costs that might indicate changing 340B savings. Sudden increases in drug expenses could signal that manufacturers have quietly restricted discounts for certain patient categories.